NRX Pharmaceuticals, Inc. Eliminates All Balance Sheet Debt
Less than 1 min read
On December 18, 2025, NRx Pharmaceuticals, Inc. announced the elimination of all balance sheet debt through equity conversion.
Key Highlights:
- Remaining $5.4 million debt repaid via equity conversion.
- No additional warrants or adjustment provisions involved.
- Company expects a debt-free balance sheet by year-end.
- Debt elimination positions company for growth in 2026.
Original SEC Filing: NRX Pharmaceuticals, Inc. [ NRXP ] - 8-K - Dec. 29, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.